Turpin Williams, Bedrani Larbi, Espin-Garcia Osvaldo, Xu Wei, Silverberg Mark S, Smith Michelle I, Garay Juan Antonio Raygoza, Lee Sun-Ho, Guttman David S, Griffiths Anne, Moayyedi Paul, Panaccione Remo, Huynh Hien, Steinhart Hillary A, Aumais Guy, Dieleman Levinus A, Turner Dan, Paterson Andrew D, Croitoru Kenneth
Department of Medicine, University of Toronto, Toronto, ON, Canada.
Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, 600 University Avenue Room 437, Toronto, Ontario, M5G 1X5, Canada.
BMC Med Genet. 2020 Oct 15;21(1):204. doi: 10.1186/s12881-020-01115-w.
Genetic analyses have identified many variants associated with the risk of inflammatory bowel disease (IBD) development. Among these variants, the ones located within the NOD2 gene have the highest odds ratio of all IBD genetic risk variants. Also, patients with Crohn's disease (CD) have been shown to have an altered gut microbiome, which might be a reflection of inflammation itself or an effect of other parameters that contribute to the risk of the disease. Since NOD2 is an intracellular pattern recognition receptor that senses bacterial peptidoglycan in the cytosol and stimulates the host immune response (Al Nabhani et al., PLoS Pathog 13:e1006177, 2017), it is hypothesized that NOD2 variants represent perfect candidates for influencing host-microbiome interactions. We hypothesized that NOD2 risk variants affect the microbiome composition of healthy first degree relative (FDR) of CD patients and thus potentially contribute to an altered microbiome state before disease onset.
Based on this, we studied a large cohort of 1546 healthy FDR of CD patients and performed a focused analysis of the association of three major CD SNPs in the coding region of the NOD2 gene, which are known to confer a 15-40-fold increased risk of developing CD in homozygous or compound heterozygous individuals.
Our results show that carriers of the C allele at rs2066845 was significantly associated with an increase in relative abundance in the fecal bacterial family Erysipelotrichaceae.
This result suggests that NOD2 polymorphisms contribute to fecal microbiome composition in asymptomatic individuals. Whether this modulation of the microbiome influences the future development of CD remains to be assessed.
基因分析已鉴定出许多与炎症性肠病(IBD)发生风险相关的变异。在这些变异中,位于NOD2基因内的变异在所有IBD遗传风险变异中具有最高的优势比。此外,克罗恩病(CD)患者的肠道微生物群已被证明发生了改变,这可能是炎症本身的一种反映,或者是导致该疾病风险的其他参数的作用结果。由于NOD2是一种细胞内模式识别受体,可在细胞质中感知细菌肽聚糖并刺激宿主免疫反应(Al Nabhani等人,《公共科学图书馆·病原体》13:e1006177,2017年),因此推测NOD2变异是影响宿主-微生物群相互作用的理想候选因素。我们假设NOD2风险变异会影响CD患者健康一级亲属(FDR)的微生物群组成,从而可能在疾病发作前导致微生物群状态改变。
基于此,我们研究了一大群1546名CD患者的健康FDR,并对NOD2基因编码区的三个主要CD单核苷酸多态性(SNP)的关联进行了重点分析,已知这些SNP在纯合或复合杂合个体中会使患CD的风险增加15至40倍。
我们的结果表明,rs2066845位点C等位基因的携带者与粪便细菌科丹毒丝菌科相对丰度的增加显著相关。
这一结果表明,NOD2多态性对无症状个体的粪便微生物群组成有影响。这种微生物群的调节是否会影响CD的未来发展仍有待评估。